Sotera Health (NASDAQ:SHC) Price Target Raised to $18.00 at JPMorgan Chase & Co.

Sotera Health (NASDAQ:SHC) had its price target lifted by JPMorgan Chase & Co. from $16.00 to $18.00 in a report issued on Friday,Benzinga reports. The firm presently has a “neutral” rating on the stock. JPMorgan Chase & Co.‘s target price would suggest a potential downside of 4.69% from the stock’s current price.

SHC has been the subject of several other research reports. The Goldman Sachs Group began coverage on shares of Sotera Health in a report on Friday, June 5th. They issued a “buy” rating and a $20.00 target price for the company. Barclays restated an “overweight” rating on shares of Sotera Health in a research note on Friday. UBS Group set a $19.00 price target on Sotera Health in a research report on Wednesday, June 24th. Citigroup reaffirmed a “buy” rating on shares of Sotera Health in a research note on Friday. Finally, Wall Street Zen downgraded Sotera Health from a “strong-buy” rating to a “buy” rating in a report on Saturday, April 11th. Eight research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, Sotera Health has a consensus rating of “Moderate Buy” and a consensus target price of $20.50.

Sotera Health Trading Down 0.1%

SHC stock traded down $0.03 during midday trading on Friday, hitting $18.89. 1,028,071 shares of the company’s stock were exchanged, compared to its average volume of 2,867,321. The business has a 50-day simple moving average of $17.07 and a two-hundred day simple moving average of $16.31. The company has a current ratio of 2.82, a quick ratio of 2.54 and a debt-to-equity ratio of 3.56. The stock has a market capitalization of $5.39 billion, a PE ratio of 45.99 and a beta of 1.77. Sotera Health has a 1-year low of $12.94 and a 1-year high of $19.85.

Sotera Health (NASDAQ:SHC) last posted its earnings results on Thursday, August 6th. The company reported $0.26 EPS for the quarter, beating analysts’ consensus estimates of $0.24 by $0.02. Sotera Health had a return on equity of 39.73% and a net margin of 9.91%.The company had revenue of $321.38 million for the quarter, compared to the consensus estimate of $309.70 million. During the same quarter in the previous year, the business earned $0.20 earnings per share. The company’s revenue for the quarter was up 9.2% on a year-over-year basis. Sotera Health has set its FY 2026 guidance at 0.950-1.010 EPS. On average, sell-side analysts predict that Sotera Health will post 0.87 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Gtcr Investment Xi Llc sold 12,735,301 shares of the stock in a transaction dated Wednesday, May 13th. The stock was sold at an average price of $15.17, for a total value of $193,194,516.17. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 15.36% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Sotera Health

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. PNC Financial Services Group Inc. boosted its stake in Sotera Health by 10.8% in the 4th quarter. PNC Financial Services Group Inc. now owns 7,204 shares of the company’s stock worth $127,000 after buying an additional 705 shares during the last quarter. Strs Ohio increased its stake in shares of Sotera Health by 17.4% during the 4th quarter. Strs Ohio now owns 4,895 shares of the company’s stock valued at $86,000 after acquiring an additional 727 shares during the last quarter. Federated Hermes Inc. lifted its holdings in shares of Sotera Health by 6.0% during the 4th quarter. Federated Hermes Inc. now owns 16,676 shares of the company’s stock worth $294,000 after acquiring an additional 944 shares during the period. First Citizens Bank & Trust Co. lifted its holdings in shares of Sotera Health by 1.5% during the 4th quarter. First Citizens Bank & Trust Co. now owns 66,266 shares of the company’s stock worth $1,169,000 after acquiring an additional 970 shares during the period. Finally, Envestnet Portfolio Solutions Inc. boosted its position in shares of Sotera Health by 1.7% in the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 64,993 shares of the company’s stock worth $1,146,000 after acquiring an additional 1,061 shares during the last quarter. 91.03% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Sotera Health

Here are the key news stories impacting Sotera Health this week:

• Positive Sentiment: Second-quarter revenue rose 9.2% year over year to $321.4 million, ahead of the $309.7 million consensus estimate. Adjusted EPS was $0.26, topping expectations of $0.24 and increasing from $0.20 a year earlier. Sotera Health Company Beats Q2 Earnings and Revenue Estimates
• Positive Sentiment: Profitability improved significantly: GAAP net income increased to $53.6 million from $8.0 million, while adjusted EBITDA grew 10% and the adjusted EBITDA margin expanded to 51.6%.
• Positive Sentiment: Growth was broad-based. Sterigenics revenue increased 7.0% on a constant-currency basis, Nordion grew 16.7%, and Nelson Labs rose 5.4%. Nordion also delivered a 160-basis-point improvement in segment margin.
• Positive Sentiment: Sotera Health raised its 2026 outlook, now expecting constant-currency revenue growth of 5.25% to 6.75%, adjusted EBITDA growth of 5.75% to 7.25%, and adjusted EPS of $0.95 to $1.01 versus the prior midpoint of expectations. Sotera Health Delivers Strong Second-Quarter and First-Half 2026 Results and Raises FY 2026 Outlook
• Positive Sentiment: Balance-sheet trends improved modestly. Net leverage declined to 3.0x, within the company’s long-term target range, liquidity reached approximately $950 million, and a term-loan repricing is expected to reduce annual interest expense by about $3.5 million.
• Neutral Sentiment: The earnings call highlighted confidence in demand for Sotera Health’s mission-critical sterilization, isotope and laboratory-testing services, but future results remain dependent on supply availability, inflation, foreign exchange and execution across its business units. Sotera Health Q2 2026 Earnings Call Transcript
• Negative Sentiment: Total debt remained high at approximately $2.2 billion. Investors also continue to face litigation, regulatory and reputational risks tied to ethylene oxide emissions, while higher costs pressured Nelson Labs’ first-half segment income.

Sotera Health Company Profile

Sotera Health Inc (NASDAQ: SHC) is a global provider of sterilization and laboratory testing services that support the medical device, pharmaceutical, life sciences and consumer product industries. Headquartered in Jacksonville, Florida, the company offers a suite of services designed to ensure products meet rigorous safety and regulatory requirements before reaching market.

Sotera Health operates through three primary service platforms. Its Sterigenics division delivers contract sterilization solutions, including ethylene oxide (EtO), gamma irradiation, electron beam and X-ray technologies.